Friday, 27 Mar 2020

You are here

Inflectra Biosimilar Ships in Late November 2016

Pfizer has announced it will ship its new FDA-approved biosimilar, Inflectra, in late November and that it will be priced at a15 percent discount to current wholesale prices.

Inflecta's generic name is infliximab-dyyb.  This same agent is already available in Europe. This would be the first biosimilar TNF inhibitor to become available in the United States.

Remicade has been a highly profitable biologic. The Wall Street Journal estimates Remicade U.S. sales to have been $4.5 billion in 2015.  Moreover, the introduction of the biosimilar Inflectra could result in at least a $1 billion in Remicade sales for 2017. (Citation source: http://buff.ly/2e2AXLd)

Issues surrounding the introduction include the magnitude of the discount and interchangeability.

While many projected a 20-30% savings for new TNFi biosimilars, Inflectra’s 15% discount is less than that. It's unclear if that amount is enough incentive to engender favorable tiered status with payors or with patients and physicians who have a long history of using Remicade.  

J&J says the average price paid for Remicade, after discounts, is 30% less than the list price, and nearly half of commercially insured patients don’t have a copay under their medical benefits. It's unclear if Pfizer will be providing the same patient assistance programs that J&J did with Remicade.

Lastly, it remains to be seen if patients will be voluntarily changed to Inflectra or have to deal with mandated insurer preference for the cheaper biosimilar.  It's likely this issue of interchangeability will be challenged by physicians or legislators.

 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Start with Anti-TNF in RA? Not So Fast

The suggestion to hit rheumatoid arthritis (RA) early and hard with biologic therapies itself took a hit in a new study.

Use of first-line etanercept (Enbrel) plus methotrexate in very early RA was not associated with a substantially higher rate of remission compared with a strategy of treat-to-target methotrexate monotherapy, a randomized open-label trial found.

Best of 2019 - The Shame Behind Adalimumab Biosimilars

JAMA has an article this week on the shift from biologic drugs to less expensive therapeutic biosimilar agents. The impact of biosimilars can be easily represented by the shift from adalimuamb - a biologic with nearly $19 billion in sales in 2018 - to any one of the four FDA approved biosimilars for adalimumab (see the daily download for slides on new adalimumab and other biosimilars).

Psoriasis Risk Increased with TNF Inhibitors in Juveniles

Children with inflammatory diseases who were treated with tumor necrosis factor (TNF) inhibitors had a higher rate of incident psoriasis than those not exposed to these biologics, a single-center retrospective study found.

The Shame Behind Adalimumab Biosimilars

JAMA has an article this week on the shift from biologic drugs to less expensive therapeutic biosimilar agents. The impact of biosimilars can be easily represented by the shift from adalimuamb - a biologic with nearly $19 billion in sales in 2018 - to any one of the four FDA approved biosimilars for adalimumab (see the daily download for slides on new adalimumab and other biosimilars).

Pain Persists Despite TNF Inhibitor Use

Control of pain in patients with rheumatoid arthritis (RA) often focuses on control of inflammation as a means to better control pain. However, a new claims data study shows that while anti-tumor necrosis factor inhibitor (TNFi) may lower the use of opioids, the reduction is nominal, suggesting that a substantial amount of pain is not adequately addressed by TNFi - a potent anti-inflammatory approach.